Advertisements


Gilead Analysts React To Failed NASH Trial: Citigroup, Wells Fargo Downgrade Biotech

One of the three widely awaited clinical trial readouts from Gilead Sciences, Inc. (NASDAQ: GILD) turned out to be a disappointment, sending its shares down sharply Tuesday.  Latest Ratings for GILD.....»»

Category: blogSource: benzingaFeb 12th, 2019

Dash for NASH trips up Gilead, but "fatty liver disease" remains biotech target

A late-stage clinical trial by Gilead Sciences Inc. failed in fatty liver disease, the company said, sending a blow to a drug industry that has seen treatments for the disease as the next big thing. The Foster City-based company's (NASDAQ: GILD) s.....»»

Category: topSource: bizjournalsFeb 12th, 2019

AT&T suffers downgrade as analysts see "many balls to juggle" with Time Warner

AT&T might have the right plan with Time Warner and fresh video options, but a new analyst note says it’s going to take a lot to navigate that journey. Analysts at Wells Fargo downgraded shares of AT&T (NYSE: T) on Wednesday amid concerns about.....»»

Category: topSource: bizjournalsAug 23rd, 2018

Aeglea Plunges On Updated Data For Arginase 1 Deficiency Candidate, Wells Fargo Downgrade

Shares of Aeglea Bio Therapeutics Inc (NASDAQ: AGLE) were slumping Tuesday following the release of data from an early-to-mid- stage trial of its lead product c read more.....»»

Category: blogSource: benzingaSep 4th, 2018

Gilead"s Failed NASH Drug Trial Drags Stock Lower

Gilead Sciences, Inc. (NASDAQ: GILD) is facing another setback, as its non-alcoholic steatohepatitis, or NASH, candidate Selonsertib flunked in a late-stage study. read more.....»»

Category: blogSource: benzingaFeb 12th, 2019

"A Negative Inflection": Wells Fargo, Morgan Stanley React To NetApp"s Q3 Sales Miss, Weak Guidance

NetApp Inc. (NASDAQ: NTAP) shares were under pressure Thursday in reaction to third-quarter results released Wednesday after the market close that included a sales miss.  The Analysts.....»»

Category: earningsSource: benzingaFeb 14th, 2019

Intercept Pharmaceuticals is one step closer to getting FDA approval for the first-ever NASH drug

Intercept Pharmaceuticals Inc. announced Tuesday that a potential therapy for the fatty liver disease known as NASH had achieved its primary goal in a Phase 3 trial, a week after Gilead Sciences Inc. announced a competing trial had failed......»»

Category: topSource: marketwatchFeb 19th, 2019

Wells Fargo Reports Q2 Earnings Beat

Wells Fargo (NYSE: WFC) reported second-quarter earnings of $1.30 per share, beating analysts $1.15 estimate. read more.....»»

Category: blogSource: benzingaJul 16th, 2019

Wells Fargo profit beats estimates on cost controls, rise in loans

Wells Fargo & Co beat analysts' estimates for quarterly profit on Tuesday, as the fourth-largest U.S. bank benefited from an uptick in lending and aggressive cost cutting......»»

Category: topSource: reutersJul 16th, 2019

A Peek Into The Markets: US Stock Futures Edge Lower Ahead Of Citigroup, Wells Fargo Earnings

Pre-open movers U.S. stock futures traded slightly lower in early pre-market trade, ahead of earnings from Ci.....»»

Category: earningsSource: benzingaJul 16th, 2019

A Peek Into The Markets: US Stock Futures Edge Lower Ahead Of Citigroup, Wells Fargo Earnings

Pre-open movers read more.....»»

Category: blogSource: benzingaJul 16th, 2019

Wall Street flat after two days of record closes

The market is poised to react to earnings from JPMorgan Chase, Wells Fargo, Johnson & Johnson and others......»»

Category: topSource: foxnewsJul 16th, 2019

Wall Street closes at fresh records for second-straight day

Citigroup reported results on Monday, while JPMorgan Chase and Wells Fargo follow on Tuesday......»»

Category: topSource: foxnewsJul 15th, 2019

Wall Street trades lower as earnings season begins

Citigroup reports results on Monday, while JPMorgan Chase and Wells Fargo follow on Tuesday......»»

Category: topSource: foxnewsJul 15th, 2019

What to Expect When Goldman Sachs, JPMorgan and Wells Fargo Report Tuesday

Practically all the major banks are coming out with their earnings this week. We have already seen Citigroup report with a decent bottom-line beat. In fact a few of these banks are coming out on........»»

Category: blogSource: 247wallstJul 15th, 2019

Wall Street opens at all-time highs as 2Q earnings season begins

Citigroup reports results on Monday, while JPMorgan Chase and Wells Fargo follow on Tuesday......»»

Category: topSource: foxnewsJul 15th, 2019

Benzinga"s Top Upgrades, Downgrades For July 15, 2019

Top Upgrades Wells Fargo upgraded Gilead Sciences, Inc. (NASDAQ: GILD) from Market Perform to Outperform. Gilead rose 0.6% to $66.65 in pre-market trading. read more.....»»

Category: blogSource: benzingaJul 15th, 2019

Wall Street poised for increases ahead of 2Q earnings season

Citigroup reports results on Monday, while JPMorgan Chase and Wells Fargo follow on Tuesday......»»

Category: topSource: foxnewsJul 15th, 2019

Gilead upgraded to Outperform from Market Perform at Wells Fargo

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 15th, 2019

JPMorgan, Wells Fargo, Citigroup, Goldman Sachs and More Major Financial Earnings This Week

24/7 Wall St. has put together a preview of some of the major financial companies kicking off the new earnings reporting season. Markets have been pushed to record highs, and these major banks........»»

Category: blogSource: 247wallstJul 14th, 2019

JPMorgan, Wells Fargo And Citigroup Among Banks Preparing To Report Q2

JPMorgan, Wells Fargo And Citigroup Among Banks Preparing To Report Q2.....»»

Category: topSource: seekingalphaJul 11th, 2019